Eltoprazine - Elto Pharma

Drug Profile

Eltoprazine - Elto Pharma

Alternative Names: DU-28853; Eltoprazine

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Solvay
  • Developer Elto Pharma; PsychoGenics; Solvay
  • Class Antidepressants; Antipsychotics; Piperazines; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists; Serotonin 1B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Drug-induced dyskinesia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder
  • Phase II Aggression; Drug-induced dyskinesia
  • No development reported Cognition disorders
  • Discontinued Psychotic disorders

Most Recent Events

  • 01 Dec 2017 Elto Pharma plans a phase III clinical development programme for Attention-deficit hyperactivity disorder
  • 01 Dec 2017 Elto Pharma plans a phase II clinical trial programme for Psychotic disorders (Alzheimer's disease)
  • 17 Apr 2017 Phase-II development is ongoing for Drug-induced dyskinesia in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top